Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial

J Clin Oncol. 2023 Mar 20;41(9):1788. doi: 10.1200/JCO.22.02098. Epub 2023 Jan 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Dexamethasone / therapeutic use
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local* / drug therapy
  • Survival Analysis

Substances

  • elotuzumab
  • Antibodies, Monoclonal, Humanized
  • Dexamethasone